EDIT Stock Price Today (September 2026) — Editas Medicine, Inc. Analysis & Key Metrics 2026-09-03
Editas Medicine, Inc. (EDIT) is trading at $3.08, up 0.00% today (as of September 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $6.00 (94.8% upside).
- Volatility remains elevated (74.81% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (2.32% YoY) alongside significant competitive pressures.
EDIT Stock Analysis: Key Metrics & Valuation (September 2026)
Concise, actionable data for investors
Editas Medicine, Inc. - Historical Price & Volume
Market Cap
Enterprise Value: $289.18M
P/E Ratio
Forward P/E: -4.06
Revenue Growth
Year over Year
Analyst Target
+94.8% upside potential
Key Investor Questions About EDIT
What investors need to know before buying
Based on current market data, EDIT presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 52.37)
- Fundamentals say: Caution warranted (high leverage concerns)
EDIT's growth trajectory depends on its ability to expand within the Biotechnology sector while managing margin pressures.
- Future growth will depend on performance in core Biotechnology operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for EDIT investors include debt exposure and competitive dynamics in the Biotechnology industry.
- $15.51M in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Biotechnology.
52-Week Trading Range
Over the past year, EDIT stock traded between $1.66 and $4.54—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 74.81% annualized volatility and β=2.05, the stock exhibits high sensitivity to market moves—making EDIT suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
Lower institutional support combined with high short selling points to negative sentiment.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
4 Gene-Editing Biotech Stocks Worth Watching for Long-Term Gains
CRSP, NTLA, BEAM and EDIT offer distinct gene-editing opportunities, spanning commercial validation, late-stage catalysts and promising early-stage programs.
Moderna’s Newfound War Chest Opens Door for 4 Strategic Acquisition Targets
Moderna's stock just surged in a way that transforms the company from a cash-burning vaccine maker into a serious acquirer, and four biotech targets already sit within striking range of its newly loaded war chest.
Is Editas Medicine (EDIT) Outperforming Other Medical Stocks This Year?
Here is how Editas Medicine (EDIT) and Amylyx Pharmaceuticals, Inc. (AMLX) have performed compared to their sector so far this year.
EDIT Q2 Earnings Beat Estimates, Revenues Rise, Pipeline in Focus
Editas beats Q2 estimates as collaboration revenues surge, while EDIT-401 advanced toward clinical testing with encouraging preclinical data.
Editas Medicine (EDIT) Reports Q2 Loss, Beats Revenue Estimates
Editas (EDIT) delivered earnings and revenue surprises of +50.00% and +524.80%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Geron (GERN) Reports Q2 Loss, Beats Revenue Estimates
Geron (GERN) delivered earnings and revenue surprises of -100.00% and +4.49%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Why Is Editas (EDIT) Down 12.4% Since Last Earnings Report?
Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026?
One company dominates with an approved therapy, while the other bets on in vivo innovation. See how their financials and risk profiles stack up for 2026.
Some Analysts Just Cut Their Editas Medicine, Inc. (NASDAQ:EDIT) Estimates
Market forces rained on the parade of Editas Medicine, Inc. ( NASDAQ:EDIT ) shareholders today, when the analysts...
EDIT's Q1 Loss Narrower Than Expected, Pipeline in Focus
Editas narrows Q1 loss as costs fall, but revenues drop sharply. Pipeline focus shifts to in vivo gene editing and lead candidate EDIT-401.
Explore More Analysis for EDIT
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Frequently Asked Questions
Common investor questions about Editas Medicine, Inc.
Editas Medicine, Inc. (EDIT) is currently trading at $3.08. The RSI (14-day) is at 52.4, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $6.00 implies 94.8% upside from current levels. Volatility is high at 74.8% annualized, meaning significant price swings are common. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Editas Medicine, Inc. (EDIT): The trailing P/E ratio is -4.67, which is below the market average of ~20-22, suggesting the stock may be undervalued relative to peers. The forward P/E is -4.06. Price-to-Book is 4.49. Price-to-Sales is 10.06. Valuation should be compared to Biotechnology industry peers for context, as different sectors trade at different multiples.
Based on 8 analysts covering EDIT, the consensus price target is $6.00. This represents a 94.8% upside from the current price of $3.08. The range spans from a low target of $1.00 to a high target of $15.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Editas Medicine, Inc. (EDIT) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Editas Medicine, Inc. (EDIT) investors include: 1. High volatility (74.8% annualized)—the stock can experience significant daily price swings. 2. Elevated short interest (14.5% of float) suggests significant bearish sentiment. 3. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 4. Biotechnology sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Editas Medicine, Inc.'s (EDIT) current debt and financial health profile: Total debt stands at $15.51M. The debt-to-equity ratio is 14.73, which is conservative and indicates a strong balance sheet with low leverage. The current ratio is 3.19, indicating strong short-term liquidity. The quick ratio is 3.13. The company holds $211.64M in cash and equivalents. Free cash flow is negative at $-44,316,000, which could limit the company's ability to manage debt obligations.